A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma

NCT05603039 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Liver Cancer

Interventions

DRUG: QL1706
DRUG: QL1604
DRUG: Bevacizumab

Sponsor

Qilu Pharmaceutical Co., Ltd.